메뉴 건너뛰기




Volumn 6, Issue , 2012, Pages 355-362

Introduction to the use of belatacept: A fusion protein for the prevention of post transplant kidney rejection

Author keywords

Belatacept; Costimulation; Organ transplantation

Indexed keywords

BASILIXIMAB; BELATACEPT; CD28 ANTIGEN; CD40 ANTIGEN; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

EID: 84872259157     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S27565     Document Type: Review
Times cited : (16)

References (43)
  • 1
    • 0033524482 scopus 로고    scopus 로고
    • A two-step, two-signal model for the primary activation of precursor helper T cells
    • Bretscher PA. A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A. 1999;96(1): 185-190.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , Issue.1 , pp. 185-190
    • Bretscher, P.A.1
  • 2
    • 10844292763 scopus 로고    scopus 로고
    • Immunosuppressive drugs for kidney transplantation
    • Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729.
    • (2004) N Engl J Med , vol.351 , Issue.26 , pp. 2715-2729
    • Halloran, P.F.1
  • 3
    • 65349189555 scopus 로고    scopus 로고
    • Costimulatory pathways in transplantation: Challenges and new developments
    • Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: challenges and new developments. Immunol Rev. 2009;229(1):271-293.
    • (2009) Immunol Rev , vol.229 , Issue.1 , pp. 271-293
    • Li, X.C.1    Rothstein, D.M.2    Sayegh, M.H.3
  • 5
    • 0035202768 scopus 로고    scopus 로고
    • The immunological synapse and CD28-CD80 interactions
    • Bromley SK, Iaboni A, Davis SJ, et al. The immunological synapse and CD28-CD80 interactions. Nat Immunol. 2001;2(12):1159-1166.
    • (2001) Nat Immunol , vol.2 , Issue.12 , pp. 1159-1166
    • Bromley, S.K.1    Iaboni, A.2    Davis, S.J.3
  • 7
    • 0031727486 scopus 로고    scopus 로고
    • The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells
    • McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev. 1998;165:231-247.
    • (1998) Immunol Rev , vol.165 , pp. 231-247
    • McAdam, A.J.1    Schweitzer, A.N.2    Sharpe, A.H.3
  • 8
    • 33748428203 scopus 로고    scopus 로고
    • T-cell costimulation - biology, therapeutic potential, and challenges
    • Sharpe AH, Abbas AK. T-cell costimulation - biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973-975.
    • (2006) N Engl J Med , vol.355 , Issue.10 , pp. 973-975
    • Sharpe, A.H.1    Abbas, A.K.2
  • 9
    • 0029914089 scopus 로고    scopus 로고
    • Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions
    • Greene JL, Leytze GM, Emswiler J, et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996;271(43):26762-26771.
    • (1996) J Biol Chem , vol.271 , Issue.43 , pp. 26762-26771
    • Greene, J.L.1    Leytze, G.M.2    Emswiler, J.3
  • 10
    • 0035059417 scopus 로고    scopus 로고
    • Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
    • Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol. 2001;19:225-252.
    • (2001) Annu Rev Immunol , vol.19 , pp. 225-252
    • Salomon, B.1    Bluestone, J.A.2
  • 11
    • 0028484545 scopus 로고
    • CTLA-4 can function as a negative regulator of T cell activation
    • Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405-413.
    • (1994) Immunity , vol.1 , Issue.5 , pp. 405-413
    • Walunas, T.L.1    Lenschow, D.J.2    Bakker, C.Y.3
  • 12
    • 0030744132 scopus 로고    scopus 로고
    • Functions of CD40 on B cells, dendritic cells and other cells
    • van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9(3):330-337.
    • (1997) Curr Opin Immunol , vol.9 , Issue.3 , pp. 330-337
    • van Kooten, C.1    Banchereau, J.2
  • 13
    • 0031944607 scopus 로고    scopus 로고
    • CD40 and CD154 in cell-mediated immunity
    • Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol. 1998;16:111-135.
    • (1998) Annu Rev Immunol , vol.16 , pp. 111-135
    • Grewal, I.S.1    Flavell, R.A.2
  • 14
    • 0034665321 scopus 로고    scopus 로고
    • Host CD40 ligand deficiency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis
    • Shimizu K, Schönbeck U, Mach F, Libby P, Mitchell RN. Host CD40 ligand defciency induces long-term allograft survival and donor-specific tolerance in mouse cardiac transplantation but does not prevent graft arteriosclerosis. J Immunol. 2000;165(6):3506-3518.
    • (2000) J Immunol , vol.165 , Issue.6 , pp. 3506-3518
    • Shimizu, K.1    Schönbeck, U.2    Mach, F.3    Libby, P.4    Mitchell, R.N.5
  • 15
    • 0033965079 scopus 로고    scopus 로고
    • Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand
    • Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000;6(2):114.
    • (2000) Nat Med , vol.6 , Issue.2 , pp. 114
    • Kawai, T.1    Andrews, D.2    Colvin, R.B.3    Sachs, D.H.4    Cosimi, A.B.5
  • 16
    • 65349188127 scopus 로고    scopus 로고
    • Translating costimulation blockade to the clinic: Lessons learned from three pathways
    • Ford ML, Larsen C P. Translating costimulation blockade to the clinic: lessons learned from three pathways. Immunol Rev. 2009;229(1): 294-306.
    • (2009) Immunol Rev , vol.229 , Issue.1 , pp. 294-306
    • Ford, M.L.1    Larsen, C.P.2
  • 18
    • 12644262358 scopus 로고    scopus 로고
    • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
    • Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA. 1997;94(16):8789-8794.
    • (1997) Proc Natl Acad Sci USA , vol.94 , Issue.16 , pp. 8789-8794
    • Kirk, A.D.1    Harlan, D.M.2    Armstrong, N.N.3
  • 20
    • 15844404353 scopus 로고    scopus 로고
    • Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
    • Larsen C P, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996;381(6581):434-438.
    • (1996) Nature , vol.381 , Issue.6581 , pp. 434-438
    • Larsen, C.P.1    Elwood, E.T.2    Alexander, D.Z.3
  • 21
    • 20044386299 scopus 로고    scopus 로고
    • Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties
    • Larsen C P, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5(3): 443-453.
    • (2005) Am J Transplant , vol.5 , Issue.3 , pp. 443-453
    • Larsen, C.P.1    Pearson, T.C.2    Adams, A.B.3
  • 22
    • 67649122193 scopus 로고    scopus 로고
    • Costimulatory blockade with belatacept in clinical and experimental transplantation - a review
    • Emamaullee J, Toso C, Merani S, Shapiro AM. Costimulatory blockade with belatacept in clinical and experimental transplantation - a review. Expert Opin Biol Ther. 2009;9(6):789-796.
    • (2009) Expert Opin Biol Ther , vol.9 , Issue.6 , pp. 789-796
    • Emamaullee, J.1    Toso, C.2    Merani, S.3    Shapiro, A.M.4
  • 23
    • 0035180065 scopus 로고    scopus 로고
    • Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: Their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance
    • Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001;182:18-32.
    • (2001) Immunol Rev , vol.182 , pp. 18-32
    • Sakaguchi, S.1    Sakaguchi, N.2    Shimizu, J.3
  • 24
    • 51849108540 scopus 로고    scopus 로고
    • The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation
    • Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant. 2008;8(10):2086-2096.
    • (2008) Am J Transplant , vol.8 , Issue.10 , pp. 2086-2096
    • Bluestone, J.A.1    Liu, W.2    Yabu, J.M.3
  • 25
    • 84864127871 scopus 로고    scopus 로고
    • Time-varying belata-cept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients
    • Zhou Z, Shen J, Hong Y, Kaul S, Pfster M, Roy A. Time-varying belata-cept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012;92(2):251-257.
    • (2012) Clin Pharmacol Ther , vol.92 , Issue.2 , pp. 251-257
    • Zhou, Z.1    Shen, J.2    Hong, Y.3    Kaul, S.4    Pfster, M.5    Roy, A.6
  • 26
    • 23944502334 scopus 로고    scopus 로고
    • Costimulation blockade with belata-cept in renal transplantation
    • Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belata-cept in renal transplantation. N Engl J Med. 2005;353(8):770-781.
    • (2005) N Engl J Med , vol.353 , Issue.8 , pp. 770-781
    • Vincenti, F.1    Larsen, C.2    Durrbach, A.3
  • 27
    • 77956528156 scopus 로고    scopus 로고
    • Five-year safety and efficacy of belatacept in renal transplantation
    • Vincenti F, Blancho G, Durrbach A, et al. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol. 2010;21(9): 1587-1596.
    • (2010) J Am Soc Nephrol , vol.21 , Issue.9 , pp. 1587-1596
    • Vincenti, F.1    Blancho, G.2    Durrbach, A.3
  • 28
    • 65549169583 scopus 로고    scopus 로고
    • Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation
    • Latek R, Fleener C, Lamian V, et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009;87(6):926-933.
    • (2009) Transplantation , vol.87 , Issue.6 , pp. 926-933
    • Latek, R.1    Fleener, C.2    Lamian, V.3
  • 29
    • 76949101581 scopus 로고    scopus 로고
    • A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
    • Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010;10(3):535-546.
    • (2010) Am J Transplant , vol.10 , Issue.3 , pp. 535-546
    • Vincenti, F.1    Charpentier, B.2    Vanrenterghem, Y.3
  • 30
    • 0344553377 scopus 로고    scopus 로고
    • Heterologous immunity: An overlooked barrier to tolerance
    • Adams AB, Pearson TC, Larsen C P. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev. 2003;196:147-160.
    • (2003) Immunol Rev , vol.196 , pp. 147-160
    • Adams, A.B.1    Pearson, T.C.2    Larsen, C.P.3
  • 31
    • 34447646310 scopus 로고    scopus 로고
    • Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses
    • Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifcally with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111-122.
    • (2007) Immunity , vol.27 , Issue.1 , pp. 111-122
    • Butte, M.J.1    Keir, M.E.2    Phamduy, T.B.3    Sharpe, A.H.4    Freeman, G.J.5
  • 32
    • 80054851680 scopus 로고    scopus 로고
    • Costimulatory pathways in transplantation
    • Pilat N, Sayegh MH, Wekerle T. Costimulatory pathways in transplantation. Semin Immunol. 2011;23(4):293-303.
    • (2011) Semin Immunol , vol.23 , Issue.4 , pp. 293-303
    • Pilat, N.1    Sayegh, M.H.2    Wekerle, T.3
  • 33
    • 76949090842 scopus 로고    scopus 로고
    • A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
    • Durrbach A, Prestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010;10(3):547-557.
    • (2010) Am J Transplant , vol.10 , Issue.3 , pp. 547-557
    • Durrbach, A.1    Prestana, J.M.2    Pearson, T.3
  • 34
    • 79955544132 scopus 로고    scopus 로고
    • Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)
    • Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011;91(9):976-983.
    • (2011) Transplantation , vol.91 , Issue.9 , pp. 976-983
    • Vanrenterghem, Y.1    Bresnahan, B.2    Campistol, J.3
  • 35
    • 78650831358 scopus 로고    scopus 로고
    • Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies
    • Larsen C P, Grinyó J, Medina-Pestana J, et al. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010;90(12):1528-1535.
    • (2010) Transplantation , vol.90 , Issue.12 , pp. 1528-1535
    • Larsen, C.P.1    Grinyó, J.2    Medina-Pestana, J.3
  • 36
    • 84857190451 scopus 로고    scopus 로고
    • Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT)
    • Abstract 229
    • Florman S, Becker T, Bresnahan B, et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation (BENEFIT and BENEFIT-EXT). Am J Transplant. 2011;11 (Suppl S2):28-559 [Abstract 229].
    • (2011) Am J Transplant , vol.11 , Issue.SUPPL. S2 , pp. 28-559
    • Florman, S.1    Becker, T.2    Bresnahan, B.3
  • 37
    • 84855674077 scopus 로고    scopus 로고
    • Belatacept: A new biologic and its role in kidney transplantation
    • Su VC, Harrison J, Rogers C, Ensom MH. Belatacept: a new biologic and its role in kidney transplantation. Ann Pharmacother. 2012;46(1): 57-67.
    • (2012) Ann Pharmacother , vol.46 , Issue.1 , pp. 57-67
    • Su, V.C.1    Harrison, J.2    Rogers, C.3    Ensom, M.H.4
  • 38
    • 79953687090 scopus 로고    scopus 로고
    • Belatacept: A novel biologic for maintenance immunosuppression after renal transplantation
    • Martin ST, Tichy EM, Gabardi S. Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation. Pharmacotherapy. 2011;31(4):394-407.
    • (2011) Pharmacotherapy , vol.31 , Issue.4 , pp. 394-407
    • Martin, S.T.1    Tichy, E.M.2    Gabardi, S.3
  • 39
    • 78650887509 scopus 로고    scopus 로고
    • Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients
    • Ferguson R, Grinyó J, Vincenti F, et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011;11(1):66-76.
    • (2011) Am J Transplant , vol.11 , Issue.1 , pp. 66-76
    • Ferguson, R.1    Grinyó, J.2    Vincenti, F.3
  • 41
    • 24644437846 scopus 로고    scopus 로고
    • Incidence of cancer after immunosuppressive treatment for heart transplantation
    • Ippoliti G, Rinaldi M, Pellegrini C, Viganò M. Incidence of cancer after immunosuppressive treatment for heart transplantation. Crit Rev Oncol Hematol. 2005;56(1):101-113.
    • (2005) Crit Rev Oncol Hematol , vol.56 , Issue.1 , pp. 101-113
    • Ippoliti, G.1    Rinaldi, M.2    Pellegrini, C.3    Viganò, M.4
  • 42
    • 84872234221 scopus 로고    scopus 로고
    • NULOJIX® (belatacept) [package Insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available from, Accessed August 23
    • NULOJIX® (belatacept) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2011. Available from: http://packageinserts.bms.com/pi/pi_nulojix.pdf. Accessed August 23, 2012.
    • (2012)
  • 43
    • 78650818523 scopus 로고    scopus 로고
    • An integrated safety profile analysis of belatacept in kidney transplant recipients
    • Grinyó J, Charpentier B, Pestana JM, et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010;90(12):1521-1527.
    • (2010) Transplantation , vol.90 , Issue.12 , pp. 1521-1527
    • Grinyó, J.1    Charpentier, B.2    Pestana, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.